CBL controls a tyrosine kinase network involving AXL, SYK and LYN in nilotinib‐resistant chronic myeloid leukaemia
暂无分享,去创建一个
B. Robert | V. Prouzet-Mauléon | E. Lippert | V. Praloran | F. Mahon | A. Sirvent | J. Pasquet | S. Roche | I. Vigon | W. Leconet | V. Desplat | A. Villacreces | P. Dumas | R. Gioia | V. Lagarde | C. Trégoat | Arnaud Villacreces | Romain Gioia
[1] K. Davies,et al. The TAM family: phosphatidylserine-sensing receptor tyrosine kinases gone awry in cancer , 2014, Nature Reviews Cancer.
[2] F. Penault-Llorca,et al. Preclinical validation of AXL receptor as a target for antibody-based pancreatic cancer immunotherapy , 2014, Oncogene.
[3] J. Aster,et al. SYK is a critical regulator of FLT3 in acute myeloid leukemia. , 2014, Cancer cell.
[4] P. Carmeliet,et al. Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma. , 2013, Blood.
[5] M. Caligiuri,et al. Inhibition of the receptor tyrosine kinase Axl impedes activation of the FLT3 internal tandem duplication in human acute myeloid leukemia: implications for Axl as a potential therapeutic target. , 2013, Blood.
[6] G. Robert,et al. Mechanisms of AXL overexpression and function in Imatinib-resistant chronic myeloid leukemia cells , 2011, Oncotarget.
[7] D. Bearss,et al. Targeting Axl and Mer Kinases in Cancer , 2011, Molecular Cancer Therapeutics.
[8] E. Lippert,et al. Quantitative phosphoproteomics revealed interplay between Syk and Lyn in the resistance to nilotinib in chronic myeloid leukemia cells. , 2011, Blood.
[9] Douglas B. Evans,et al. Overexpression of receptor tyrosine kinase Axl promotes tumor cell invasion and survival in pancreatic ductal adenocarcinoma , 2011, Cancer.
[10] D. Mukhopadhyay,et al. The novel receptor tyrosine kinase Axl is constitutively active in B-cell chronic lymphocytic leukemia and acts as a docking site of nonreceptor kinases: implications for therapy. , 2011, Blood.
[11] Y. Hitoshi,et al. R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer. , 2010, Cancer research.
[12] Bjørn Tore Gjertsen,et al. Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival , 2009, Proceedings of the National Academy of Sciences.
[13] G. Feldmann,et al. The Axl receptor tyrosine kinase confers an adverse prognostic influence in pancreatic cancer and represents a new therapeutic target , 2009, Cancer biology & therapy.
[14] B. Turcq,et al. Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression. , 2008, Cancer research.
[15] Ming-Tseh Lin,et al. Receptor tyrosine kinase AXL is induced by chemotherapy drugs and overexpression of AXL confers drug resistance in acute myeloid leukemia. , 2008, Cancer letters.
[16] A. Boureux,et al. The Src-like adaptor protein regulates PDGF-induced actin dorsal ruffles in a c-Cbl-dependent manner , 2008, Oncogene.
[17] N. Donato,et al. Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells. , 2008, Blood.
[18] C. Récher,et al. A critical role for Lyn in acute myeloid leukemia. , 2008, Blood.
[19] Paloma Valverde,et al. Effects of Gas6 and hydrogen peroxide in Axl ubiquitination and downregulation. , 2005, Biochemical and biophysical research communications.
[20] I. Dikic,et al. Src Phosphorylation of Alix/AIP1 Modulates Its Interaction with Binding Partners and Antagonizes Its Activities* , 2005, Journal of Biological Chemistry.
[21] W. Cavenee,et al. Alix/AIP1 Antagonizes Epidermal Growth Factor Receptor Downregulation by the Cbl-SETA/CIN85 Complex , 2004, Molecular and Cellular Biology.
[22] Sujay K. Singh,et al. Hydrogen Peroxide Activates NF-κB through Tyrosine Phosphorylation of IκBα and Serine Phosphorylation of p65 , 2003, Journal of Biological Chemistry.
[23] S. Pierce,et al. Cbl-b Negatively Regulates B Cell Antigen Receptor Signaling in Mature B Cells through Ubiquitination of the Tyrosine Kinase Syk , 2003, The Journal of experimental medicine.
[24] A. Scharenberg,et al. Activation of Syk Tyrosine Kinase Is Required for c-Cbl-mediated Ubiquitination of FcεRI and Syk in RBL Cells* , 2002, The Journal of Biological Chemistry.
[25] R. Herrmann,et al. Axl expression is associated with adverse prognosis and with expression of Bcl-2 and CD34 in de novo acute myeloid leukemia (AML): results from a multicenter trial of the Swiss Group for Clinical Cancer Research (SAKK) , 1999, Leukemia.
[26] J. Melo,et al. The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. , 1996, Blood.
[27] D. Huhn,et al. Axl, a novel receptor tyrosine kinase isolated from chronic myelogenous leukemia. , 1993, Seminars in hematology.
[28] M. Yoshida,et al. Characterization of the promoter region of the src family gene lyn and its trans activation by human T-cell leukemia virus type I-encoded p40tax , 1992, Molecular and cellular biology.
[29] R. Espinosa,et al. axl, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase , 1991, Molecular and cellular biology.
[30] O. Witte,et al. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. , 1990, Science.
[31] G. Daley,et al. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. , 1990, Science.
[32] N. Heisterkamp,et al. Oncogene activation by chromosomal translocation in chronic myelocytic leukemia. , 1986, Cold Spring Harbor symposia on quantitative biology.
[33] J. Rowley,et al. Chromosome abnormalities in malignant hematologic diseases. , 1982, Advances in cancer research.
[34] W. N.,et al. THE PATHOLOGICAL SOCIETY OF GREAT BRITAIN AND IRELAND , 1906 .